" class="no-js "lang="en-US"> AACR Archives - Medtech Alert
Monday, April 15, 2024

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023

Temple Therapeutics, a biotechnology company pioneering a female-focused precision medicine approach, presented new in vitro […]

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate

Nutcracker Therapeutics, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology […]

Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable […]

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors

IDEAYA Biosciences, a precision medicine oncology company committed to the discovery and development of targeted […]

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]

Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer

Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced […]

Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR)

Sapience Therapeutics, a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics […]

New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer

Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more